F. Estelle R. Simons
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
F. Estelle R. Simons has a total of 361 co-authors. Here are the top co-authors by number of shared publications:
Keith J. Simons
Faculty of Pharmacy, Department of Pediatrics and Child Health, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
5 shared publications- Pascal Demoly
University Hospital of Montpellier
3 shared publications - Victoria Cardona
Hospital Universitari Vall d'Hebron Barcelona Spain
3 shared publications Xiaochen Gu
Faculty of Pharmacy, University of Manitoba, Room 202 Pharmacy Building, 50 Sifton Road, R3T 2N2, Winnipeg, MB, Canada
3 shared publications- Adnan Custovic
National Heart and Lung Institute, Imperial College London London UK
2 shared publications - Alvaro Augusto Cruz
Fundaçao ProAR and (Faculdade de Medicina da) Universidade Federal da Bahia Salvador Bahia Brazil
2 shared publications
Latest Publications
- Open Access
- 4 April 2018
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 14 (1) , 1-11
Critical view of anaphylaxis epidemiology: open questions and new perspectives
In contrast to the majority of allergic or hypersensitivity conditions, worldwide anaphylaxis epidemiological data remain sparse with low accuracy, which hampers comparable morbidity statistics. Data can differ widely depending on a number of variables. In the current document we reviewed the forms on which anaphylaxis has been defined and classified; and how it can affect epidemiological data. With regards to the methods used to capture morbidity statistics, we observed the impact of the anaphylaxis coding utilizing the World Health Organization’s International Classification of Diseases. As an outcome and depending on the anaphylaxis definition, we extracted the cumulative incidence, which may not reflect the real number of new cases. The new ICD-11 anaphylaxis subsection developments and critical view of morbidity statistics data are discussed in order to reach new perspectives on anaphylaxis epidemiology.
- 4 April 2018
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 14 (1) , 1-11
Open AccessCritical view of anaphylaxis epidemiology: open questions and new perspectives
In contrast to the majority of allergic or hypersensitivity conditions, worldwide anaphylaxis epidemiological data remain sparse with low accuracy, which hampers comparable morbidity statistics. Data can differ widely depending on a number of variables. In the current document we reviewed the forms on which anaphylaxis has been defined and classified; and how it can affect epidemiological data. With regards to the methods used to capture morbidity statistics, we observed the impact of the anaphylaxis coding utilizing the World Health Organization’s International Classification of Diseases. As an outcome and depending on the anaphylaxis definition, we extracted the cumulative incidence, which may not reflect the real number of new cases. The new ICD-11 anaphylaxis subsection developments and critical view of morbidity statistics data are discussed in order to reach new perspectives on anaphylaxis epidemiology.
- Open Access
- 10 November 2017
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 13 (1) , 1-4
Adherence with epinephrine autoinjector prescriptions in primary care
The aim of this study was to estimate primary adherence for epinephrine autoinjector (EA) prescriptions in primary care practices in Manitoba, Canada. A retrospective analysis of electronic medical record and administrative data was performed to determine primary adherence, defined as dispensation of a new EA prescription within 90 days of the date the prescription was written. Multivariable logistic regression models were used to test predictors of filling an EA prescription. Of 1212 EA prescriptions written between 2012 and 2014, only 69.9% (N = 847) were filled. An increased number of prescriptions for non-EA mediations was associated with an increased odds ratio of not filling an EA prescription. This is the first study in Canada to examine adherence for EA prescriptions. The non-adherence rate identified is higher than rates previously reported in the literature, and indicates that many EA prescriptions for adults seen in primary care may never be filled. It also suggests that prescriptions of EAs for all patients at risk of anaphylaxis in community settings should consistently be accompanied by concise information about the importance of having the EA prescription filled and having the EA readily available.
- 10 November 2017
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 13 (1) , 1-4
Open AccessAdherence with epinephrine autoinjector prescriptions in primary care
The aim of this study was to estimate primary adherence for epinephrine autoinjector (EA) prescriptions in primary care practices in Manitoba, Canada. A retrospective analysis of electronic medical record and administrative data was performed to determine primary adherence, defined as dispensation of a new EA prescription within 90 days of the date the prescription was written. Multivariable logistic regression models were used to test predictors of filling an EA prescription. Of 1212 EA prescriptions written between 2012 and 2014, only 69.9% (N = 847) were filled. An increased number of prescriptions for non-EA mediations was associated with an increased odds ratio of not filling an EA prescription. This is the first study in Canada to examine adherence for EA prescriptions. The non-adherence rate identified is higher than rates previously reported in the literature, and indicates that many EA prescriptions for adults seen in primary care may never be filled. It also suggests that prescriptions of EAs for all patients at risk of anaphylaxis in community settings should consistently be accompanied by concise information about the importance of having the EA prescription filled and having the EA readily available.
- Open Access
- 23 October 2017
- Published by Wiley in Clinical and Translational Allergy
- Vol. 7 (1) , 1-16
CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel NetworK) Good Practice in allergic rhinitis: a SUNFRAIL report
A Good Practice is a practice that works well, produces good results, and is recommended as a model. MACVIA-ARIA Sentinel Network (MASK), the new Allergic Rhinitis and its Impact on Asthma (ARIA) initiative, is an example of a Good Practice focusing on the implementation of multi-sectoral care pathways using emerging technologies with real life data in rhinitis and asthma multi-morbidity. The European Union Joint Action on Chronic Diseases and Promoting Healthy Ageing across the Life Cycle (JA-CHRODIS) has developed a checklist of 28 items for the evaluation of Good Practices. SUNFRAIL (Reference Sites Network for Prevention and Care of Frailty and Chronic Conditions in community dwelling persons of EU Countries), a European Union project, assessed whether MASK is in line with the 28 items of JA-CHRODIS. A short summary was proposed for each item and 18 experts, all members of ARIA and SUNFRAIL from 12 countries, assessed the 28 items using a Survey Monkey-based questionnaire. A visual analogue scale (VAS) from 0 (strongly disagree) to 100 (strongly agree) was used. Agreement equal or over 75% was observed for 14 items (50%). MASK is following the JA-CHRODIS recommendations for the evaluation of Good Practices.
- 23 October 2017
- Published by Wiley in Clinical and Translational Allergy
- Vol. 7 (1) , 1-16
Open AccessCHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel NetworK) Good Practice in allergic rhinitis: a SUNFRAIL report
A Good Practice is a practice that works well, produces good results, and is recommended as a model. MACVIA-ARIA Sentinel Network (MASK), the new Allergic Rhinitis and its Impact on Asthma (ARIA) initiative, is an example of a Good Practice focusing on the implementation of multi-sectoral care pathways using emerging technologies with real life data in rhinitis and asthma multi-morbidity. The European Union Joint Action on Chronic Diseases and Promoting Healthy Ageing across the Life Cycle (JA-CHRODIS) has developed a checklist of 28 items for the evaluation of Good Practices. SUNFRAIL (Reference Sites Network for Prevention and Care of Frailty and Chronic Conditions in community dwelling persons of EU Countries), a European Union project, assessed whether MASK is in line with the 28 items of JA-CHRODIS. A short summary was proposed for each item and 18 experts, all members of ARIA and SUNFRAIL from 12 countries, assessed the 28 items using a Survey Monkey-based questionnaire. A visual analogue scale (VAS) from 0 (strongly disagree) to 100 (strongly agree) was used. Agreement equal or over 75% was observed for 14 items (50%). MASK is following the JA-CHRODIS recommendations for the evaluation of Good Practices.
- Open Access
- 30 December 2016
- Published by Wiley in Clinical and Translational Allergy
- Vol. 6 (1) , 1-14
ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle
The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization workshop in 1999. The initial goals were (1) to propose a new allergic rhinitis classification, (2) to promote the concept of multi-morbidity in asthma and rhinitis and (3) to develop guidelines with all stakeholders that could be used globally for all countries and populations. ARIA—disseminated and implemented in over 70 countries globally—is now focusing on the implementation of emerging technologies for individualized and predictive medicine. MASK [MACVIA (Contre les Maladies Chroniques pour un Vieillissement Actif)-ARIA Sentinel NetworK] uses mobile technology to develop care pathways for the management of rhinitis and asthma by a multi-disciplinary group and by patients themselves. An app (Android and iOS) is available in 20 countries and 15 languages. It uses a visual analogue scale to assess symptom control and work productivity as well as a clinical decision support system. It is associated with an inter-operable tablet for physicians and other health care professionals. The scaling up strategy uses the recommendations of the European Innovation Partnership on Active and Healthy Ageing. The aim of the novel ARIA approach is to provide an active and healthy life to rhinitis sufferers, whatever their age, sex or socio-economic status, in order to reduce health and social inequalities incurred by the disease.
- 30 December 2016
- Published by Wiley in Clinical and Translational Allergy
- Vol. 6 (1) , 1-14
Open AccessARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle
The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization workshop in 1999. The initial goals were (1) to propose a new allergic rhinitis classification, (2) to promote the concept of multi-morbidity in asthma and rhinitis and (3) to develop guidelines with all stakeholders that could be used globally for all countries and populations. ARIA—disseminated and implemented in over 70 countries globally—is now focusing on the implementation of emerging technologies for individualized and predictive medicine. MASK [MACVIA (Contre les Maladies Chroniques pour un Vieillissement Actif)-ARIA Sentinel NetworK] uses mobile technology to develop care pathways for the management of rhinitis and asthma by a multi-disciplinary group and by patients themselves. An app (Android and iOS) is available in 20 countries and 15 languages. It uses a visual analogue scale to assess symptom control and work productivity as well as a clinical decision support system. It is associated with an inter-operable tablet for physicians and other health care professionals. The scaling up strategy uses the recommendations of the European Innovation Partnership on Active and Healthy Ageing. The aim of the novel ARIA approach is to provide an active and healthy life to rhinitis sufferers, whatever their age, sex or socio-economic status, in order to reduce health and social inequalities incurred by the disease.
- 29 September 2006
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 27 (9) , 427-435
Epinephrine for the treatment of anaphylaxis: do all 40 mg sublingual epinephrine tablet formulations with similar in vitro characteristics have the same bioavailability?
Epinephrine autoinjectors are underutilized in the first aid emergency treatment of anaphylaxis in the community; so non‐invasive sublingual epinephrine administration is being proposed. In order to determine the effect of changing excipients on the bioavailability of sublingual epinephrine, four distinct fast‐disintegrating epinephrine 40 mg tablet formulations, A, B, C and D, were manufactured using direct compression. All formulations were evaluated for tablet hardness (H), disintegration time (DT) and wetting time (WT). In a prospective 5‐way crossover study, four sublingual formulations and epinephrine 0.3 mg i.m. as a control were tested sequentially in a validated rabbit model. Blood samples were collected before dosing and at intervals afterwards. Epinephrine plasma concentrations were measured using HPLC‐EC. All tablet formulations met USP standards for weight variation and content uniformity, and resulted in similar mean H, DT and WT (n=6). The area under the curve (AUC), maximum concentration (Cmax) and time at which Cmax was achieved (Tmax) did not differ significantly after the sublingual administration of formulation A and epinephrine 0.3 mg i.m. The AUC after B, C and D were significantly lower (p<0.05) than after epinephrine 0.3 mg i.m. These results suggest that the selection of excipients used in these tablet formulations can affect the bioavailability of sublingually administered epinephrine. Copyright © 2006 John Wiley & Sons, Ltd.
- 29 September 2006
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 27 (9) , 427-435
Epinephrine for the treatment of anaphylaxis: do all 40 mg sublingual epinephrine tablet formulations with similar in vitro characteristics have the same bioavailability?
Epinephrine autoinjectors are underutilized in the first aid emergency treatment of anaphylaxis in the community; so non‐invasive sublingual epinephrine administration is being proposed. In order to determine the effect of changing excipients on the bioavailability of sublingual epinephrine, four distinct fast‐disintegrating epinephrine 40 mg tablet formulations, A, B, C and D, were manufactured using direct compression. All formulations were evaluated for tablet hardness (H), disintegration time (DT) and wetting time (WT). In a prospective 5‐way crossover study, four sublingual formulations and epinephrine 0.3 mg i.m. as a control were tested sequentially in a validated rabbit model. Blood samples were collected before dosing and at intervals afterwards. Epinephrine plasma concentrations were measured using HPLC‐EC. All tablet formulations met USP standards for weight variation and content uniformity, and resulted in similar mean H, DT and WT (n=6). The area under the curve (AUC), maximum concentration (Cmax) and time at which Cmax was achieved (Tmax) did not differ significantly after the sublingual administration of formulation A and epinephrine 0.3 mg i.m. The AUC after B, C and D were significantly lower (p<0.05) than after epinephrine 0.3 mg i.m. These results suggest that the selection of excipients used in these tablet formulations can affect the bioavailability of sublingually administered epinephrine. Copyright © 2006 John Wiley & Sons, Ltd.
- 1 June 2006
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 7 (2) , E72-E78
Fast-disintegrating sublingual tablets: Effect of epinephrine load on tablet characteristics
The aim of this study was to evaluate the effect of increasing epinephrine load on the characteristics of fast-disintegrating sublingual tablets for the potential emergency treatment of anaphylaxis. Four tablet formulations, A, B, C, and D, containing 0%, 6%, 12%, and 24% of epinephrine bitartrate, respectively, and microcrystalline cellulose:low-substituted hydroxypropyl cellulose (9∶1), were prepared by direct compression, at a range of compression forces. Tablet weight variation, content uniformity, hardness, disintegration time, wetting time, and friability were measured for each formulation at each compression force. All 4 tablet formulations at each compression force were within the United States Pharmacopeia (USP) limits for weight variation and content uniformity. A linear increase in compression force resulted in an exponential increase in hardness for all formulations, a linear increase in disintegration and wetting times of A, and an exponential increase in disintegration and wetting times of B, C, and D. At a mean±SD hardness of ≥2.3±0.2 kg, all tablet formulations passed the USP friability test. At a mean±SD hardness of ≤3.1±0.2 kg, all tablet formulations resulted in disintegration and wetting times of <10 seconds and <30 seconds, respectively. Tablets with drug loads from 0% to 24% epinephrine can be formulated with hardness, disintegration times, and wetting times suitable for sublingual administration.
- 1 June 2006
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 7 (2) , E72-E78
Fast-disintegrating sublingual tablets: Effect of epinephrine load on tablet characteristics
The aim of this study was to evaluate the effect of increasing epinephrine load on the characteristics of fast-disintegrating sublingual tablets for the potential emergency treatment of anaphylaxis. Four tablet formulations, A, B, C, and D, containing 0%, 6%, 12%, and 24% of epinephrine bitartrate, respectively, and microcrystalline cellulose:low-substituted hydroxypropyl cellulose (9∶1), were prepared by direct compression, at a range of compression forces. Tablet weight variation, content uniformity, hardness, disintegration time, wetting time, and friability were measured for each formulation at each compression force. All 4 tablet formulations at each compression force were within the United States Pharmacopeia (USP) limits for weight variation and content uniformity. A linear increase in compression force resulted in an exponential increase in hardness for all formulations, a linear increase in disintegration and wetting times of A, and an exponential increase in disintegration and wetting times of B, C, and D. At a mean±SD hardness of ≥2.3±0.2 kg, all tablet formulations passed the USP friability test. At a mean±SD hardness of ≤3.1±0.2 kg, all tablet formulations resulted in disintegration and wetting times of <10 seconds and <30 seconds, respectively. Tablets with drug loads from 0% to 24% epinephrine can be formulated with hardness, disintegration times, and wetting times suitable for sublingual administration.
- 1 February 2006
- Published by Wiley in Clinical & Experimental Allergy Reviews
- Vol. 6 (S1) , 1-5
Drugs used in paediatric allergy: should we conduct studies in children or extrapolate from adults?
- 1 February 2006
- Published by Wiley in Clinical & Experimental Allergy Reviews
- Vol. 6 (S1) , 1-5
Drugs used in paediatric allergy: should we conduct studies in children or extrapolate from adults?
- 1 February 2006
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 117 (2) , 398-403
Sublingual epinephrine tablets versus intramuscular injection of epinephrine: Dose equivalence for potential treatment of anaphylaxis
- 1 February 2006
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 117 (2) , 398-403
Sublingual epinephrine tablets versus intramuscular injection of epinephrine: Dose equivalence for potential treatment of anaphylaxis
- 1 September 2004
- Published by Springer Nature in The AAPS Journal
- Vol. 6 (3) , 7-12
Cetirizine from topical phosphatidylcholine-hydrogenated liposomes: Evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model
Cetirizine, an effective, minimally sedating, second-generation H1-antihistamine is widely used orally to treat allergic skin disorders. This study was per
- 1 September 2004
- Published by Springer Nature in The AAPS Journal
- Vol. 6 (3) , 7-12
Cetirizine from topical phosphatidylcholine-hydrogenated liposomes: Evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model
Cetirizine, an effective, minimally sedating, second-generation H1-antihistamine is widely used orally to treat allergic skin disorders. This study was per
- 1 March 2001
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 124 (1-3) , 403-405
Mosquito Allergy: Recombinant Mosquito Salivary Antigens for New Diagnostic Tests
In patients with mosquito allergy, lack of a readily available, sensitive, specific, safe test is the major obstacle to accurate diagnosis. Three recombinant mosquito salivary antigens, rAed a 1 (68 kD), rAed a 2 (37 kD) and rAed a 3 (30 kD), from Aedes aegypti have been cloned, expressed, purified and characterized. All three recombinant antigens are shared by Aedes vexans and other mosquito species, and all have been found to have biologic activity in humans. In recent studies, 43% of 28 mosquito bite test-positive subjects had a positive skin test to rAed a 1, 11% to rAed a 2 and 32% to rAed a 3. The sizes of the skin test reactions to the recombinant antigens correlated with the sizes of the A. aegypti bite test reactions. None of 15 A. aegypti bite test-negative subjects had a positive skin test to any of the recombinant antigens. Recombinant mosquito salivary antigens will facilitate the diagnosis of mosquito allergy.
- 1 March 2001
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 124 (1-3) , 403-405
Mosquito Allergy: Recombinant Mosquito Salivary Antigens for New Diagnostic Tests
In patients with mosquito allergy, lack of a readily available, sensitive, specific, safe test is the major obstacle to accurate diagnosis. Three recombinant mosquito salivary antigens, rAed a 1 (68 kD), rAed a 2 (37 kD) and rAed a 3 (30 kD), from Aedes aegypti have been cloned, expressed, purified and characterized. All three recombinant antigens are shared by Aedes vexans and other mosquito species, and all have been found to have biologic activity in humans. In recent studies, 43% of 28 mosquito bite test-positive subjects had a positive skin test to rAed a 1, 11% to rAed a 2 and 32% to rAed a 3. The sizes of the skin test reactions to the recombinant antigens correlated with the sizes of the A. aegypti bite test reactions. None of 15 A. aegypti bite test-negative subjects had a positive skin test to any of the recombinant antigens. Recombinant mosquito salivary antigens will facilitate the diagnosis of mosquito allergy.